findmyKOL

Vivian Shi, MD

Enriched profile

Professor of Dermatology; Director, Clinical Trials Unit, Department of Dermatology · University of Washington

ORCIDNPI
Region🇺🇸 Seattle, WA · West · United StatesSpecialtyDermatologyFocusHidradenitis Suppurativa and Treatments+4
Active KOLLatest publication2026Online presenceverified 2026Payments2021–2025NIH fundingNone on fileWhy? →

Vivian Shi is Professor of Dermatology; Director, Clinical Trials Unit, Department of Dermatology at University of Washington. OpenAlex indexes 412 publications with 5,522 citations (h-index 40); ClinicalTrials.gov lists 5 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 10% of Dermatology profiles in the findmyKOL directory.

Data verified 14 Aug 2026

Overview

Updated 27 Aug 2026

Vivian Shi, MD, is Professor of Dermatology at University of Washington, Department of Dermatology. The public record shows 412 publications with 5,522 citations (h-index 40), centered on Hidradenitis Suppurativa and Treatments, Dermatology and Skin Diseases, Colorectal and Anal Carcinomas. It also documents an investigator role on 5 registered clinical trials, industry payments reported by 21 companies.

  • Most recent indexed publication: 2026 · American journal of clinical dermatology
  • Top research focus: Hidradenitis Suppurativa and Treatments
  • 5 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 21 companies

Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Atopic Dermatitis / Eczema2 trialsAcne / Hidradenitis2 trialsHidradenitis Suppurativa2 trialsLymphadenitis2 trialsEczema1 trialFever1 trialCoccidioidomycosis1 trial

Research focus

OpenAlex concept fingerprint
Hidradenitis Suppurativa and TreatmentsDermatology and Skin DiseasesColorectal and Anal CarcinomasAllergic Rhinitis and SensitizationAcne and Rosacea Treatments and Effects

Drugs & molecules

across trials, industry payments and publications
Dupixentgeneric · DupilumabClinical trialsIndustry payments74Publications4Bimzelxgeneric · BimekizumabClinical trialsIndustry payments60Publications1Ebglyssgeneric · LebrikizumabClinical trialsIndustry payments6Publications1

Works with

trial sponsors and companies reporting payments
UCB, Inc.Clinical trialsIndustry payments102Novartis Pharmaceuticals CorporationClinical trialsIndustry payments89Abbvie Inc.Clinical trialsIndustry payments87

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
412publications

Distinct works indexed by OpenAlex, matched via ORCID; 74 in PubMed.

5,522citations

Total citations across indexed works.

40h-index

Hirsch index (OpenAlex). i10-index 133.

Clinical & industry

trials, payments and federal funding
5clinical trials

Investigator role on registered studies.

View trials
21companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments
0NIH grants

Federally funded research awards.

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 27 Aug 2026

Listed as an investigator on 5 registered studies on ClinicalTrials.gov. The most recent:

Industry payments

Updated 27 Aug 2026

21 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cancer & immunology

    60.3%
    TNF inhibitor48.4%
    Humira(Cf) Pen100%
    Part D13 patients
    Interleukin-17A Antagonist11.9%
    Cosentyx Sensoready (2 Pens)100%
    Part D<11 patients
  • Dermatology

    39.7%
    Corticosteroid23%
    Triamcinolone Acetonide100%
    Part D12 patients
    Interleukin-4 Receptor alpha Antagonist16.7%
    Dupixent Pen100%
    Part D<11 patients
Where care is delivered (Part B)64.4% facility · 35.6% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →

Congress activity

Updated 27 Aug 2026

2 congress contributions (2017–2025) across AACR, ASCO per OpenAlex. The most recent:

Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.

Publications

Updated 27 Aug 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

Network

Updated 27 Aug 2026

The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.

Online presence

Updated 27 Aug 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Owned accounts

public accounts run by this person
  • Doximity

    doximity.com/pub/vivian-shi-md

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com

Mentions by others

where others cite or feature them
  • X / Twitter

    x.com/nationaleczema/status/1985018840019796449

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →x.com
  • LinkedIn

    LinkedIn profile (auth-walled, SERP snippet lists her as Associate Professor of Dermatology, stale title, but confirms identity/handle)

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 27 Aug 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record

Editorial & leadership roles

journal and society appointments
  • Director

    Clinical Trials Unit, UW Department of Dermatology

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →derm.uw.edu
  • Founder and Director

    Hidradenitis Suppurativa Specialty Clinic, UW Medicine

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →derm.uw.edu
  • Editor

    reference textbooks on hidradenitis suppurativa, atopic dermatitis, and clinical dermatology topics

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →derm.uw.edu
4 more roles behind the reveal.Reveal →

Awards & honors

honors on the public record

Secondary affiliations

appointments beyond the home institution

Media & interviews

press, podcasts and appearances
3 more media items behind the reveal.Reveal →

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.